MedTrace Logo

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

NCT01620554 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2012-06-15

No results posted yet for this study

Summary

Prospective, multicenter, double-blind, phase II, randomized, dose-response study in 5 parallel groups (dose-range).

Conditions

Interventions

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

BF2.649

1 capsule per week during 2 weeks

DRUG

Placebo

1 capsule per week during 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Evelyne De Paillette, MD · Bioprojet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01620554 on ClinicalTrials.gov